MA47202A - Anticorps humains dirigés contre la toxine hémolysine a de s.aureus - Google Patents

Anticorps humains dirigés contre la toxine hémolysine a de s.aureus

Info

Publication number
MA47202A
MA47202A MA047202A MA47202A MA47202A MA 47202 A MA47202 A MA 47202A MA 047202 A MA047202 A MA 047202A MA 47202 A MA47202 A MA 47202A MA 47202 A MA47202 A MA 47202A
Authority
MA
Morocco
Prior art keywords
hemolysin
aureus
toxin
directed against
human antibodies
Prior art date
Application number
MA047202A
Other languages
English (en)
Inventor
Alida Coppi
Peter Mason
William Olson
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of MA47202A publication Critical patent/MA47202A/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267Gram-positive bacteria
    • C07K16/1271Micrococcaceae (F); Staphylococcaceae (F), e.g. Staphylococcus (G)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MA047202A 2017-01-03 2018-01-02 Anticorps humains dirigés contre la toxine hémolysine a de s.aureus MA47202A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762441786P 2017-01-03 2017-01-03

Publications (1)

Publication Number Publication Date
MA47202A true MA47202A (fr) 2019-11-13

Family

ID=61054509

Family Applications (1)

Application Number Title Priority Date Filing Date
MA047202A MA47202A (fr) 2017-01-03 2018-01-02 Anticorps humains dirigés contre la toxine hémolysine a de s.aureus

Country Status (19)

Country Link
US (3) US10463748B2 (fr)
EP (1) EP3565835A1 (fr)
JP (2) JP2020504759A (fr)
KR (1) KR20190101435A (fr)
CN (1) CN110167960B (fr)
AR (1) AR110719A1 (fr)
AU (1) AU2018206531A1 (fr)
BR (1) BR112019013375A2 (fr)
CA (1) CA3048989A1 (fr)
CL (1) CL2019001836A1 (fr)
CO (1) CO2019006902A2 (fr)
EA (1) EA201991643A1 (fr)
IL (1) IL267600A (fr)
MA (1) MA47202A (fr)
MX (1) MX2019007784A (fr)
MY (1) MY199976A (fr)
PH (1) PH12019501425A1 (fr)
TW (2) TWI781130B (fr)
WO (1) WO2018128973A1 (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI781130B (zh) 2017-01-03 2022-10-21 美商再生元醫藥公司 抗金黃色葡萄球菌溶血素a毒素之人類抗體
WO2020106461A2 (fr) * 2018-11-08 2020-05-28 Celldex Therapeutics, Inc. Anticorps anti-mertk et leurs méthodes d'utilisation
CN109400704B (zh) * 2018-11-14 2020-07-21 珠海泰诺麦博生物技术有限公司 一种抗金黄色葡萄球菌α-溶血素的抗体及其应用
AU2019384790A1 (en) * 2018-11-21 2021-03-18 Regeneron Pharmaceuticals, Inc. Anti-staphylococcus antibodies and uses thereof
US12459991B2 (en) 2019-02-12 2025-11-04 Regeneron Pharmaceuticals, Inc. Compositions and methods for using bispecific antibodies to bind complement and a target antigen
CN113966343A (zh) 2019-06-11 2022-01-21 瑞泽恩制药公司 结合PcrV的抗PcrV抗体、包含抗PcrV抗体的组合物及其使用方法
CN112538112B (zh) * 2019-09-20 2023-10-27 迈威(上海)生物科技股份有限公司 抗α-溶血素的抗体及其应用
KR20210095781A (ko) 2020-01-24 2021-08-03 주식회사 에이프릴바이오 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물
CN113444173A (zh) 2020-03-25 2021-09-28 兴盟生物医药(苏州)有限公司 金黄色葡萄球菌α-毒素特异性抗体及其应用
US20230399416A1 (en) * 2020-10-27 2023-12-14 Mirimgene Co., Ltd. Wars-neutralizing antibody and use thereof
JP2024503425A (ja) * 2021-01-11 2024-01-25 星濟生物(蘇州)有限公司 黄色ブドウ球菌のα毒素を標的とした抗原結合たんぱく質およびその応用
JP2024513746A (ja) * 2021-03-22 2024-03-27 星濟生物(蘇州)有限公司 ニューモリシンを標的とした抗原結合たんぱく質およびその応用
WO2023208123A1 (fr) * 2022-04-28 2023-11-02 珠海泰诺麦博制药股份有限公司 Anticorps monoclonal entièrement humain se liant spécifiquement à la toxine hla de staphylococcus aureus
CN115894674B (zh) * 2022-12-20 2023-07-25 厦门润康源生物科技有限公司 一种用于检测冠状病毒的抗体及制备方法和应用
CN116789814B (zh) * 2023-06-27 2024-03-29 重庆原伦生物科技有限公司 一种特异性结合金黄色葡萄球菌α-溶血素的抗体及其应用

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2437213A1 (fr) 1978-09-28 1980-04-25 Cm Ind Produits cytotoxiques formes par liaison covalente de la chaine a de la ricine avec un anticorps et leur procede de preparation
GB8426463D0 (en) 1984-10-19 1984-11-28 Technology Licence Co Ltd Monoclonal antibodies
JP2003503015A (ja) 1999-05-03 2003-01-28 メダレツクス・インコーポレーテツド スタフィロコッカス・アウレウスに対するヒト抗体
US6573096B1 (en) 2000-04-01 2003-06-03 The Research Foundation At State University Of New York Compositions and methods for inhibition of cancer invasion and angiogenesis
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US20040101920A1 (en) 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
US7850962B2 (en) 2004-04-20 2010-12-14 Genmab A/S Human monoclonal antibodies against CD20
US8257740B1 (en) 2011-08-15 2012-09-04 Gp Medical, Inc. Pharmaceutical composition of nanoparticles
US8246995B2 (en) 2005-05-10 2012-08-21 The Board Of Trustees Of The Leland Stanford Junior University Hydrophobic nanotubes and nanoparticles as transporters for the delivery of drugs into cells
US7411046B2 (en) 2005-08-02 2008-08-12 Arius Research Inc Cancerous disease modifying antibodies
US8258256B2 (en) 2006-01-05 2012-09-04 The Johns Hopkins University Compositions and methods for the treatment of cancer
US7420040B2 (en) 2006-02-24 2008-09-02 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of TROP-2
RS52176B (sr) 2006-06-02 2012-08-31 Regeneron Pharmaceuticals Inc. Antitela visokog afiniteta prema humanom il-6 receptoru
EP2719397A1 (fr) 2006-06-12 2014-04-16 GlaxoSmithKline Biologicals SA Utilisation de toxine alpha pour le traitement et la prévention d'infections par le staphylocoque
US20180221466A9 (en) 2006-06-12 2018-08-09 Glaxosmithkline Biologicals S.A. Use of alpha-toxin for treating and preventing staphylococcus infections
US9181329B2 (en) 2007-08-31 2015-11-10 The University Of Chicago Methods and compositions related to immunizing against Staphylococcal lung diseases and conditions
AU2008292897B2 (en) 2007-08-31 2015-01-22 University Of Chicago Methods and compositions related to immunizing against staphylococcal lung diseases and conditions
JP5410434B2 (ja) 2007-09-28 2014-02-05 バインド セラピューティックス インコーポレイテッド ナノ粒子を用いた癌細胞の標的化
AU2009246510B2 (en) 2008-05-12 2014-02-13 Strox Biopharmaceuticals, Llc Staphylococcus aureus-specific antibody preparations
US8277812B2 (en) 2008-10-12 2012-10-02 Massachusetts Institute Of Technology Immunonanotherapeutics that provide IgG humoral response without T-cell antigen
KR101747103B1 (ko) 2009-06-26 2017-06-14 리제너론 파마슈티칼스 인코포레이티드 천연 면역글로불린 포맷을 가지는 용이하게 분리된 이중특이성 항체
EP2284193A1 (fr) 2009-08-10 2011-02-16 Kenta Biotech AG Anticorps monoclonal humain contre l'alpha-toxine dérivée du Staphylococcus aureus, et son utilisation pour le traitement ou la prévention de la formation des abcès
WO2012031260A2 (fr) 2010-09-02 2012-03-08 Excelimmune, Inc. Anticorps polyclonaux humains recombinés spécifiques du staphylocoque doré et utilisations de ceux-ci
SG10201913690SA (en) * 2011-02-08 2020-03-30 Medimmune Llc Antibodies that specifically bind staphylococcus aureus alpha toxin and methods of use
US20140286960A1 (en) 2011-07-28 2014-09-25 Cangene Corporation Staphlococcus aureus alpha-hemolysin antibodies
WO2013093693A1 (fr) * 2011-12-22 2013-06-27 Rinat Neuroscience Corp. Anticorps spécifiques de staphylococcus aureus et leurs utilisations
JP6228186B2 (ja) 2012-04-17 2017-11-08 アルサニス・バイオサイエンスズ・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 交差反応性黄色ブドウ球菌(Staphylococcusaureus)抗体
KR20150092738A (ko) 2012-11-06 2015-08-13 메디뮨 엘엘씨 에스.아우레우스 연관 질병의 치료 방법
CN105873946A (zh) * 2013-10-17 2016-08-17 阿尔萨尼斯生物科学有限责任公司 交叉反应性金黄色葡萄球菌抗体序列
TWI719938B (zh) 2014-06-19 2021-03-01 美商麥迪紐有限責任公司 多重細菌感染之治療
TWI702229B (zh) * 2014-12-19 2020-08-21 美商再生元醫藥公司 流行性感冒病毒血球凝集素之人類抗體
CN107873034A (zh) 2015-04-17 2018-04-03 阿尔萨尼斯生物科学有限责任公司 抗金黄色葡萄球菌抗体组合制剂
TWI781130B (zh) 2017-01-03 2022-10-21 美商再生元醫藥公司 抗金黃色葡萄球菌溶血素a毒素之人類抗體

Also Published As

Publication number Publication date
IL267600A (en) 2019-08-29
TWI781130B (zh) 2022-10-21
US10463748B2 (en) 2019-11-05
CA3048989A1 (fr) 2018-07-12
KR20190101435A (ko) 2019-08-30
PH12019501425A1 (en) 2020-06-15
TW202311284A (zh) 2023-03-16
JP2023011710A (ja) 2023-01-24
US10940211B2 (en) 2021-03-09
US20200016275A1 (en) 2020-01-16
EA201991643A1 (ru) 2020-01-20
CN110167960A (zh) 2019-08-23
AR110719A1 (es) 2019-04-24
MY199976A (en) 2023-12-01
WO2018128973A1 (fr) 2018-07-12
BR112019013375A2 (pt) 2020-02-11
TW201837054A (zh) 2018-10-16
EP3565835A1 (fr) 2019-11-13
US20210162059A1 (en) 2021-06-03
JP2020504759A (ja) 2020-02-13
CO2019006902A2 (es) 2019-07-31
US11571482B2 (en) 2023-02-07
CL2019001836A1 (es) 2019-10-04
CN110167960B (zh) 2023-01-13
US20180214569A1 (en) 2018-08-02
MX2019007784A (es) 2019-09-06
AU2018206531A1 (en) 2019-07-25

Similar Documents

Publication Publication Date Title
MA47202A (fr) Anticorps humains dirigés contre la toxine hémolysine a de s.aureus
EP3700416A4 (fr) Capteurs d'analyte préconnectés
EP3665140C0 (fr) Mélanges agricoles
EP3958755A4 (fr) Capteurs d'analyte préconnectés
EP3687374A4 (fr) Capteur physiologique intraoculaire
EP3740508A4 (fr) Anticorps et variants associés dirigés contre tigit
EP3589313A4 (fr) Anticorps anti-tigit
MA49034A (fr) Anticorps anti-lag3
MA47268A (fr) Anticorps anti-gpc3
EP3568192A4 (fr) Valves de cathéter
EP3672900A4 (fr) Amplificateur de levage d'élément de construction
DK3649152T3 (da) ROR1-antistoffer
EP3813710A4 (fr) Analyse d'ajustement d'implant
EP3777957A4 (fr) Structure de connexion médicale
EP3692072A4 (fr) Anticorps anti-hla-dq2.5
EP3617231A4 (fr) Anticorps anti-gpc-1
EP3847438A4 (fr) Capteurs rétrographiques
MA51134A (fr) Anticorps anti-alpha-synucléine
MA51135A (fr) Anticorps anti-alpha-synucléine
EP3837286A4 (fr) Anticorps dirigés contre znt8 humain
EP3760247A4 (fr) Séparateur de toxines
EP3648575C0 (fr) Système de plantation pour surface d'un bâtiment
MA50654A (fr) Anticorps anti-pacap
MA49257A (fr) Anticorps anti-trkb
DK3257345T3 (da) Rullende landbrugselement